

Product Datasheet

Human CLDN18.2 full length protein-VLP (orb1291767)

Description	Human Full length Claudin 18.2 Protein-VLP
Reactivity	Human
Target	CLDN18.2
Form/Appearance	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Storage	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Tag	C-Flag Tag
Note	For research use only
Source	Mammalian
MW	The Human Claudin 18.2 Protein has a predicted MW of 29 kDa. Due to PTM, the actual MW on SDS-PAGE gel is around 50kDa.
Uniprot ID	P56856
Expiration Date	6 months from date of receipt.


Biorbyt Ltd.

7 Signet Court, Swann's Road,
Cambridge, CB5 8LA, United Kingdom
Email: info@biorbyt.com, support@biorbyt.com
Phone: [+44 \(0\) 1223 859-353](tel:+44(0)1223859353) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)


Biorbyt LLC.

68 TW Alexander Drive,
Durham, NC, 27713, United States
Email: info@biorbyt.com, support@biorbyt.com
Phone: [+1 \(415\) 906-5211](tel:+1(415)9065211) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)

ELISA assay to evaluate CLDN18.2 VLP
0.5µg Human CLDN18.2 VLP per well



ELISA plates were pre-coated with 0.5µg/per well purified human CLDN18.2 VLP. Serial diluted Anti-CLDN18.2 monoclonal antibody (Zolbetuximab biosimilar; IMAB362) solutions were added, washed, and incubated with secondary antibody before ELISA reading. From above data, the EC50 for IMAB362 binding with CLDN18.2 VLP is 15.37 ng/ml.



FACS analysis of CLDN18.2 VLP. A. Negative Control 1: CLDN18.2 VLP were stained only with Goat anti-human IgG Fc-PE secondary antibody. B. Negative Control 2: Control VLP were stained with anti-CLDN18.2 antibody (Zolbetuximab biosimilar; IMAB362) at 1 µg/mL, followed by Goat anti-human IgG Fc-PE secondary antibody. C. Negative Control 3: CLDN18.2 VLP were stained with anti-BCMA antibody (an irrelevant antibody) at 1 µg/mL, followed by Goat anti-human IgG Fc-PE secondary antibody. D. CLDN18.2 VLP were stained with anti-CLDN18.2 antibody (Zolbetuximab biosimilar; IMAB362) at 1 µg/mL, followed by Goat anti-human IgG Fc-PE secondary antibody.

Biorbyt Ltd.

7 Signet Court, Swann's Road,
Cambridge, CB5 8LA, United Kingdom
Email: info@biorbyt.com, support@biorbyt.com
Phone: [+44 \(0\) 1223 859-353](tel:+44(0)1223859353) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)

Biorbyt LLC.

68 TW Alexander Drive,
Durham, NC, 27713, United States
Email: info@biorbyt.com, support@biorbyt.com
Phone: [+1 \(415\) 906-5211](tel:+1(415)9065211) | Fax: [+1 \(415\) 651-8558](tel:+1(415)6518558)